TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Decrease in airway hyperresponsiveness to mannitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma phosphorus levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma pharmacokinetics of Cannabidiol (CBD) and THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Actinic Keratoses Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peak enhancement values in abdominal aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak enhancement values in hepatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Highest enhancement difference between a hepatic lesion and background liver parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 6 minute hall walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive bHCG rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of genetic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in TMW-NI knowledge survey
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change of total hair counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fundamentals of Laparoscopy (FLS) manual Skills Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASES-E Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS Elbow Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Percentage of Fat Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Symptomatic COVID-19 at 60 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in fat and muscle thickness in the abdominal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of adenosine diphosphate-induced platelet aggregation at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline of platelet activating factor-induced platelet aggregation at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline of thrombin-induced platelet aggregation at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in plasminogen activator inhibitor-1 activity at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in soluble P-selectin levels at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immune Response at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax of pyrotinib and docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of pyrotinib and docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sero-protection rate to HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and efficacy
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in QTcF Interval with GSK573719/ Vilanterol 125/25mcg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in QTcF Interval with GSK573719 500 mcg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Preliminary anti-tumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ability of primordial follicles to respond to FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CGI - Clinical Global Impression of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma cytokine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time for Performing an Airway Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events or Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: small bowel water content area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interleukins Serum Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacterial markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cranial Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate Sustained for ≥ 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successfully Inserted Peripheral IV Catheter Placement on First Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accurate diagnosis of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New bedsores
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: absence of sperm in ejaculated semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Success of rhythm control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin thermal variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concordance between cytological findings and surgical histology results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety (Type, Frequency, Severity and Relationship of Adverse Events to Study Treatment)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Endpoint of Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Fat-graft survival volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time 0 to the last measured concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in EEG power of the slow oscillation frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in EEG power of the sleep spindles frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in cross-frequency coupling between slow oscillations and sleep spindles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: volume of oxygen consumed (VO2) at the first ventilatory threshold (SV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of hybridoma clones producing anti-glioma antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative sensory testing (QST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Bioavailability of JNJ-64417184
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Acalabrutinib Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity levels in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal proximity to the nearest pig outbreak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial proximity to the nearest pig outbreak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency and aneurysms recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Total ADHD-RS-IV Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADHD-RS-IV Score for Subgroup of Participants With Target CTN SR Dose of 400 mg/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Who Experienced at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in inhibition-switching performance on the D-KEFS CWIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TEPS Consummatory Pleasure score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in EDI-3 Body Dissatisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Symptom-free Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in Boston Bowel Preparation Scale & Ottawa Bowel Preparation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of motor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to clinical status downgrade or discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Cumulative HPV Series Initiation Vaccination Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Cumulative HPV Series Completion Vaccination Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative intrabdominal abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Fruit and vegetable intake behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with LDL-C level <70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: PLE (Phase Lag Entropy) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score on the Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correlation between CACS and LCBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Microbiota alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of nasal swab sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful treatment delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Toxicity (no grade 4) during chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sural nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline natural killer cell activity at 12-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of alveolar fibrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Root Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Belimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC [0 to t]) of Belimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box and Block Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of early POCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in frequency of smartphone use while driving
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Accurate Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home dialysis survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reports of hunger/fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete Clearance of AK lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with positive margins on pathological specimen analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient perceptions of the surgery as measured by BREAST-Q questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: freedom from atrial tachycardia/atrial fibrillation > 30 seconds without antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Size of Geographic Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Stent Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Single limb standing balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of mobile technology for transmitting vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resiliency of mobile technology for retrieval of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FMA-UE scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI DWIBS Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Showing Immunologic Response to Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of biliary strictures and biliary fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharmacokinetics of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Problem Monitor (BPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Top Problems Assessment (TPA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recurrence of bile duct stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Achieved Clinical Cure at Test of Cure Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microcirculatory function of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 3-Month Disease Control Rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Pregnancy Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Time to relapse of Major Depressive Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastroparesis Cardinal Symptom Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: local and systemic safety
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline the Brief University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA-Brief)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline the Activities of Daily Living Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline the Contextual Memory Test (CMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of patients maintaining solifenacin treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD28 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ICOS Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of symptomatic or asymptomatic VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: clinical features of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in the intensity of patient-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in Pediatric Anxiety Rating Scale (PARS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: magnetic resonance imaging changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in disease activity as measured by Rodnan Skin Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease activity as measured by patient reported Scleroderma Health Associated Questionnaire (SHAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increase of the femoral arterial flow (ΔRVAFitv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Number of days with hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Body mass index age-and-gender specific Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of heart health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in clinical severity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders after Targinact treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ridge dimensions changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in Resisting Offers of Opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Willing to Misuse Prescription Opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: arterial inflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Sustained Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of cervical length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (Area Under the Concentration Time Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Concentration of the Analyte in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic brain changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Attributional style
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in numbers of M. pneumoniae-specific ASCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes